The company said net sales for Q3 2026 (3 months) rose to $951.7 million, up 8% from $878.7 million a year earlier, and diluted EPS increased to $1.95 from $1.70.

1. 01

   The company said net sales for Q3 2026 (3 months) rose to $951.7 million, up 8% from $878.7 million a year earlier, and diluted EPS increased to $1.95 from $1.70.

2. 02

   IDEX said orders for Q3 rose 13% to $991.2 million. Organic sales increased 13% in Health & Science Technologies, 4% in Fluid & Metering Technologies and 6% in Fire & Safety/Diversified Products. The company cited AI-driven demand for data center power and semiconductor markets as the driver of growth in Health & Science Technologies.

3. 03

   The company said cash flow from operating activities for Q3 2026 was $239.5 million, and free cash flow was $214.3 million, up from $203.5 million and $188.7 million in the year-earlier period. Capital expenditures in the same quarter were $25.2 million.

4. 04

   IDEX said it expects full-year organic sales to rise 6.5% to 6.8% over the prior year, raising its previous outlook of 5% to 6%, and expects full-year adjusted diluted EPS of $8.91 to $8.96, up from its previous outlook of $8.70 to $8.85.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.